Background: Inflammation in acute coronary syndrome (ACS) can identify those at greater long-term risks for heart failure (HF) and death. The present study assessed the performance of interleukin (IL)-6, IL-8, and monocyte chemoattractant protein-1 (MCP-1) (cytokines involved in the activation and recruitment of leukocytes) in addition to known biomarkers [e.g., N-terminal probrain natriuretic peptide (NT-proBNP)] for predicting HF and death in an ACS population. Methods: In a cohort of 216 ACS patients, NT-proBNP (Elecsys ® ; Roche) and IL-6, IL-8, and MCP-1 (evidence investigator™; Randox) were measured in serial specimens collected early after symptom onset (n ‫؍‬ 723). We collected at least 2 specimens from each participant: an early specimen (median 2 h; interquartile range 2-4 h) and a later specimen (9 h; 9 -9 h), and used the later specimens' biomarker concentrations for risk stratification. Results: An increase in both IL-6 and NT-proBNP was observed but not for IL-8 or MCP-1 early after pain
monocyte chemoattractant protein-1 (MCP-1) are both chemokines that recruit neutrophils and monocytes, respectively, to the inflammatory process (9 ) . We have reported that increased baseline concentrations of CRP are predictive of long-term risk for HF and death in an ACS population (4 ) . In the present study, we sought to determine if these more specific and earlier mediators of leukocyte activation and recruitment, coupled with assessment of heart dysfunction based on N-terminal probrain natriuretic peptide (NT-proBNP) concentrations, could provide prognostic information beyond that of CRP and troponin in a cohort of chest pain patients presenting to the emergency department. Moreover, because the optimal timing for measuring cytokines is unknown in this setting, we wanted to document the cytokine profile early after chest pain onset.
Materials and Methods study population
The study population and its characteristics have been reported (4, 10 -12 ) . At the time of study enrollment in 1996, 448 consecutive unique patients presenting with symptoms suggestive of cardiac ischemia to the emergency department in a community hospital were recruited for a retrospective cardiac marker study. Time of symptom onset was solicited, and blood samples (both EDTA and heparin anticoagulated blood from all patients) were collected at specified intervals (from time of symptom onset hourly until 6 h, and then at 9, 12, 24, and 48 h) until the patient was discharged, declined further participation, or was removed from the study by those responsible for his or her care. All specimens from 1996 were frozen, predominantly at -70°C, until 2003 when the heparin specimens were thawed and cardiac troponin I (cTnI) and CRP measurements were performed on the Access ® (AccuTnI assay) and Immage ® (high-sensitivity CRP assay) instruments, respectively, from Beckman Coulter (4, 10 -12 ) . We have confirmed the stability of troponin I and CRP over time in our cohort (4 ) . For the present study, we selected only those individuals (n ϭ 216) who had at least 2 EDTA specimens available in storage. The median number of specimens per participant was 3 [interquartile range (IQR) [2] [3] [4] [5] , and all specimens (n ϭ 723) were measured with the cytokine array and NT-proBNP to provide a serial and temporal profile of the biomarkers. For the outcome analysis, we selected only 2 specimens per participant based on the following criteria: the earliest available (1st specimen) and the closest to 9 h after onset (2nd specimen). In the event that the 1st specimen obtained was Ͼ6 h after onset, then the next specimen at least 3 h later was selected as the 2nd specimen. Thus the minimum interval between specimen pairs was 3 h [median 6.5 h (IQR 5-8)]. 
biomarker measurements
In 2006, the EDTA specimens were thawed for the 1st time, and a cytokine array was measured using the evidence investigator™ (Randox) biochip platform (9, 13 ) . The biochip can assay 12 cytokines; however, a priori the decision was made to evaluate only IL-6, IL-8, and MCP-1 for the present study assessing HF and death in an ACS population. The interassay (n ϭ 20 assays) imprecision (CV), determined by measuring 3 levels of quality control material, ranged from 10.9% to 16.2% for IL-6, 8.3% to 16.1% for IL-8, and 7.6% to 13.0% for MCP-1. We measured NT-proBNP by use of the Elecsys ® 1010 (Roche), with interassay impression Ͻ7%. There is evidence to support the stability of the cytokines measured in the present study after 10 years' storage, in that the reference ranges for IL-8 and MCP-1 published in 2006 for this method were derived from samples collected as early as 1994 (9, 14 ) . IL-6 and NT-proBNP also appear to be stable during long-term storage (15) (16) (17) .
health outcomes and statistical analysis
Research ethics board approval was obtained to measure biomarkers in the stored samples and to make health outcome linkages to the Registered Persons Data Base for mortality outcomes and the Canadian Institute for Health Information Discharge Abstract Database for hospital discharges associated with HF (11 ) . Both the Registered Persons Data Base and Canadian Institute for Health Information Discharge Abstract Database (i.e., administrative databases) have been reported to be highly accurate in obtaining these endpoints (18 -21 ) . Based on the death date and earliest subsequent readmission for HF, indicators were created to reflect whether an event (death or HF readmission) occurred within 8 years postpresentation (in patients who died without previous HF readmission, follow-ups were censored at the date of death). We used biomarker concentrations (e.g., NT-proBNP, IL-6, IL-8, MCP-1) in the later (2nd) specimen to determine risk based on the hypothesis that this specimen would reflect the severity of cardiac dysfunction and the inflammatory response of the patient better than the earlier specimen. Of note, exploratory analyses using logistic regression models with the cytokines for the combined endpoint death/HF suggested no difference in long-term outcomes (e.g., at 8 years) between the 1st and 2nd specimen; however, the 2nd specimen tended to be more predictive for early outcomes (e.g., 30 days and 1 year) than the 1st specimen. The analyses were based on the following classifications. For both IL-6 and NTproBNP, we used the median concentrations at the 2nd time point (IL-6 Ͼ 6.4 ng/L and NT-proBNP Ͼ183 ng/L). We used the upper limit of normal (97.5th percentile) for IL-8 (Ͼ7.5 ng/L) and MCP-1 (Ͼ156 ng/L). For our study population (n ϭ 216), the combined endpoint (death/HF) was used for all analyses to maximize the number of events.
We constructed Kaplan-Meier curves to display time to an event (death/HF) and assessed differences between groups by use of the log-rank test. We used the Cox proportional hazard model to compare time to an event for the increased biomarkers. In keeping with our previous analyses in this cohort (4, 11 ) , we used different models to assess the risk associated with increased cytokines: model 1 adjusts for age (continuous variable), sex, history of HF, and STEMI (Q wave) at presentation; model 2 adjusts for age (continuous variable), sex, history of HF, STEMI (Q wave), presentation CRP concentration Ͼ7.44 mg/L (the concentration that optimized performance of We designated values of 0.00 -0.01 g/L as the reference group based on previous analyses showing that increases in risk occur at values Ն0.02 g/L (11, 22 ) . We used the highest cTnI concentration in the model to assess the possibility that the inflammatory markers measured increased in proportion to the extent of necrosis and thus reflected infarct size, a known determinant of prognosis. Significance of the association was based on the Wald 2 statistic, with significance set at P Ͻ0.05. We used Cox proportional hazard models to assess the ability of combinations of IL-6, NT-proBNP, and MCP-1 and their interactions to predict death/HF. Models were constructed for IL-6 alone, IL-6 and MCP-1 (with and without interaction), IL-6 and NT-proBNP (with and without interaction), and IL-6, MCP-1, and NT-proBNP (with and without interactions), with the likelihood ratio as well as the significance of the association based on the Wald 2 statistic (P Ͻ0.05). We based between-group comparisons of central tendency on the Wilcoxon and Kruskal-Wallis tests. Analyses were performed using SAS version 9.1.3 and GraphPad Prism version 5.00.
Results
For the 216 participants (61% male), the median age (25th-75th percentile) was 66 years (53-76) ( Table 1) . At the time of study enrollment in 1996, 19.4% of the participants were diagnosed with acute myocardial infarction based on WHO Monitoring Cardiovascular Disease (MONICA) criteria (10, 23 ) . Applying the European Society of Cardiology/American College of Cardiology criteria retrospectively based on the peak cTnI concentrations resulted in 44.4% of participants having a cTnI concentration Ͼ99th percentile (Ͼ0.04 g/L) (10, 24, 25 ) . There were increases in both NT-proBNP and IL-6 concentrations, but not IL-8 or MCP-1, early after the onset of chest pain (Fig. 1) . This result was also evident by the increased concentrations in the 2nd specimen (median 9 h after onset) vs the 1st specimen (median 2 h after onset) ( Table 2) .
Kaplan-Meier analysis using the concentrations from the later (2nd) specimen demonstrated that increased concentrations of each of the cytokines and NT-proBNP resulted in a greater probability for death/HF over the 8 years after emergency department presentation (Fig. 2) . Cox proportional hazard models adjusting for age, sex, history of HF, and STEMI at presentation yielded signif- Clinical Chemistry 53, No. 12, 2007 icant hazard ratios (HRs) for IL-6, MCP-1, and NTproBNP, but not for IL-8, at all 3 time points. After adjusting for high CRP and peak cTnI concentrations, only the increased IL-6 and MCP-1 groups were significantly associated with an increased risk for death/HF at 6 months; however, at 2 and 8 years, increased IL-6, MCP-1, and NT-proBNP all had significant HRs (Table 3 ). To assess whether there was a synergistic relationship between IL-6, NT-proBNP, and MCP-1 for predicting longterm death/HF in our population, a time-to-event analysis (Cox proportional model) was performed with IL-6 alone and with MCP-1 and NT-proBNP alone and together to assess their combinations and interactions (Table 4). Including IL-6, MCP-1, and NT-proBNP in the model resulted in a significantly higher likelihood ratio for death/HF compared with IL-6 alone and the combination of IL-6 with either MCP-1 or NT-proBNP.
Discussion
The present study confirms earlier work indicating that inflammation is a strong predictor of future death and/or HF in patients with ACS (1-4, 26 -28 ) . This study is different from others in that the analyzed cytokines were measured early after the onset of pain, a time when they have roles in the activation and recruitment of leukocytes during the inflammatory process. In addition, they were assessed as predictors of both short-term (6 months) and long-term (8 years) outcomes after adjusting for cTnI, using a cutoff value below the 99th percentile previously shown to be of prognostic importance (11 ) , and after adjusting for CRP values previously found to be predictive (4 ).
A rising pattern was observed for both IL-6 and NT-proBNP but not for the chemokines (IL-8 and MCP-1), suggesting that IL-6 and/or NT-proBNP production may be an acute response to myocardial injury. However, it did not appear to be related to the extent of cardiac injury as reflected by the Cox proportional analysis using peak cTnI concentrations to correct for this possibility. Thus, it seems that the exuberance of the acute inflammatory response is an important predictor of both intermediate and long-term prognosis independent of the extent of (32, 33 ) , but to our knowledge this result is the 1st indication that increases are independent predictors for long-term death/HF in an ACS population.
Because of the small sample size, we cannot separate the risks associated for either HF or death alone or include a large number of covariates in our modeling. Moreover, our population does not represent a contemporary cohort. This approach is a strength in the sense that it provides a better natural history; however, prospective studies are necessary that take into account present medical management in patients with ACS (more medical and mechanical interventions). Also, because our aim was to evaluate and document changes in biomarkers over time, we opted to include only individuals with at least 2 specimens at least 3 h apart. The 216 individuals selected for the study were, on average, older than the 232 individuals who were excluded (64.7 vs 60.5 years; P ϭ 0.002), they stayed in the hospital longer for their initial event, and they had higher cTnI peak concentrations (median 0.04 vs 0.01 g/L). However, important for this analysis, there was no difference in presentation CRP concentrations, and the endpoints at 30 days and 1 year between the included and excluded patient groups were not different.
This study builds on previous work by using a validated analytical platform for cytokine measurements and reference ranges for IL-8 and MCP-1 for classifying elevations (9, 13 ) . Moreover, the cutoffs used in this study closely resemble other reported values in the literature for risk stratification for IL-6 (26 ) and the median value for NT-proBNP in an ACS population (34 ) .
In conclusion, these data support the findings that inflammation and cardiac dysfunction in ACS indicate a poor prognosis, independent of the extent of myocardial necrosis, in that ACS patients with increased IL-6, MCP-1, and NT-proBNP are at greater risk for subsequent HF and death.
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